Search results for "droni."

Measurement of pion and proton response and longitudinal shower profiles up to 20 nuclear interaction lengths with the ATLAS Tile calorimeter

2010

The response of pions and protons in the energy range of 20–180 GeV, produced at CERN's SPS H8 test-beam line in the ATLAS iron–scintillator Tile hadron calorimeter, has been measured. The test-beam configuration allowed the measurement of the longitudinal shower development for pions and protons up to 20 nuclear interaction lengths. It was found that pions penetrate deeper in the calorimeter than protons. However, protons induce showers that are wider laterally to the direction of the impinging particle. Including the measured total energy response, the pion-to-proton energy ratio and the resolution, all observations are consistent with a higher electromagnetic energy fraction in pion-indu…

Study of BESIII trigger efficiencies with the 2018 J/psi data

2021

Using a dedicated data sample taken in 2018 on the $J/\psi$ peak, we perform a detailed study of the trigger efficiencies of the BESIII detector. The efficiencies are determined from three representative physics processes, namely Bhabha-scattering, dimuon production and generic hadronic events with charged particles. The combined efficiency of all active triggers approaches $100\%$ in most cases with uncertainties small enough as not to affect most physics analyses.

Upgrade of ATLAS hadronic Tile Calorimeter for the High-Luminosity LHC

2022

The Tile Calorimeter (TileCal) is a sampling hadronic calorimeter covering the central region of the ATLAS experiment, with steel as absorber and plastic scintillators as active medium. The High-Luminosity phase of LHC, delivering five times the LHC nominal instantaneous luminosity, is expected to begin in 2028. TileCal will require new electronics to meet the requirements of a 1 MHz trigger, higher ambient radiation, and to ensure better performance under high pile-up conditions. Both the on- and off-detector TileCal electronics will be replaced during the shutdown of 2026-2028. The TileCal upgrade program has included extensive R&D and test beam studies. A Demonstrator module with reverse…

Production and decay of charmed mesons at the Z resonance

1991

Abstract In a sample of 190 000 hadronic Z decays, three signals of charm production are observed: two from the exclusive decays D ° → K − π + and D ∗+ → D °π + → K − π + π + and one in the transverse-momentum distribution of soft hadrons relative to the nearest jet. The features of these signals are in good agreement with expectations based on the standard model and previous measurements of the branching fractions. The number of D ∗± → K ± π ± π ± per hadronic decay of the Z is measured to be (5.11±0.34) × 10 −3 , and the branching ratio B(D 0 → K − π + ) is (3.62 ± 0.34 ± 0.44)%. Charm hadronization has been studied. The average fraction of the beam energy carried by the D ∗ meson is foun…

Production of (anti-)He3 and (anti-)H3 in p-Pb collisions at sNN=5.02 TeV

2020

The transverse momentum (pT) differential yields of (anti-)3He and (anti-)3H measured in p-Pb collisions at √sNN = 5.02 TeV with ALICE at the Large Hadron Collider (LHC) are presented. The ratios of the pTintegrated yields of (anti-)3He and (anti-)3H to the proton yields are reported, as well as the pT dependence of the coalescence parameters B3 for (anti-)3 He and (anti-)3H. For (anti-)3He, the results obtained in four classes of the mean charged-particle multiplicity density are also discussed. These results are compared to predictions from a canonical statistical hadronization model and coalescence approaches. An upper limit on the total yield of 4He is determined.

THE ROLE OF HIGH-DOSE VITAMIN D IN RISK REDUCTION OF OSTEONECROSIS OF THE JAW IN CANCER PATIENTS RECEIVING ZOLEDRONIC ACID

Osteonecrosis of the jaw (ONJ) is a serious complication of oncological patients after or during drug therapy, whose manifestations range from asymptomatic to aspects requiring extensive operative treatment and adversely affecting patient’s qualify of life. Taking in account that the lack of supplementation vitamin D causes hypovitaminosis, increasing bone renewal, losing bone mass, and in severe cases determing osteomalacia (one of the risk factors for ONJ) and that the probability of developing ONJ increases significantly during the first 3 years of treatment, the main objective of the present study is to assess whether the implementation of high-dose vitamin D in oncologic patients treat…

In Sicilia zoledronic acid is cost effective when compared to both alendronate and risedronate and this choice shows a small uncertainty range.

2008

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and …

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SR…

Molecular target therapy for bone metastasis : starting a new era with denosumab, a RANKL inhibitor

2014

Abstract: Introduction: The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting. Areas covered: Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the …